NIH-funded research to be published on-line for free

23 September 2007

The US Congress is considering legislation that would require the authors of scientific articles that have received National Institutes of Health grants to submit their papers for free public inspection on the federal agency's web site. Copyright advocates claim this will reduce intellectual property protection and harm the peer-reviewed journals' economic viability, Technology Today reports. The legislation was approved by the House of Representatives in a spending bill for the NIH (HR3043).

The dispute mirrors similar demands by anti-patent advocates who argue that drug companies benefit from research that is funded by the NIH, without adequate compensation being made to taxpayers, from whose funds the drug industry allegedly benefits.

Patrick Ross, executive director of the Copyright Alliance, said that would-be publishers would be deterred from conducting peer review and publishing NIH-funded research by the immediate prospect of the article appearing elsewhere for free.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight